Verv Technologies cashes up to advance its technology through the U.S. regulatory process.
The CEO of a Sudbury medical technology company said it’s about a year away from taking its transformative home blood-testing kit to the market.
Jeff Sutton, one of the founders of Verv Technologies, expects their blood analyzer device, dubbed Vi, to be in small batch production in early 2023 before it’s finally introduced to consumers later in the year.
“We’re opening up a new market and the market is enormous,” said Sutton.
The 11-employee startup is in the early phases of presenting its technology before the Food and Drug Administration in the U.S., their targeted market.
The company recently secured $3.8 million in capital from Randox Laboratories of the United Kingdom to help them navigate the final stretch of their path toward commercialization.